Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

DL(CO), or -- Death In the case of FVC or DL(CO), the decline must be confirmed at two consecutive visits at least 6 weeks apart. 3. Categorical assessment of absolute change from Baseline to Week 72 in percent predicted FVC 4. Change from Baseline to Week 72 in dyspnea measured by the University of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) 5. Change from Baseline to Week 72 in the percent predicted Hb-corrected DL(CO) 6. Change from Baseline to Week 72 in the worst oxygen saturation by pulse oximetry (SpO2) measurement observed during the Six-Minute Walk Test 7. Change from Baseline to Week 72 in distance walked in the Six- Minute Walk Test

Regarding RECAP, all eligible patients from CAPACITY have been enrolled in this on-going open-label roll-over study from CAPACITY to evaluate the long-term safety of pirfenidone in patients with IPF.

The results of CAPACITY will be presented at the 2009 International Conference of the American Thoracic Society (ATS) in San Diego, and InterMune plans to publish the results of CAPACITY in a peer-reviewed journal.

About Pirfenidone

Preclinical and in-vitro evidence had shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Prior to the current results, data were presented from one Phase 3 study and four Phase 2 clinical trials in more than 400 patients which suggested that pirfenidone may positively affect lung function and disease progression in patients with IPF. In those clinical studies, pirfenidone was generally safe and well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pir
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 2010 Advanced Life Sciences Holdings, Inc. ... company engaged in the discovery, development and commercialization of ... and respiratory diseases, today announced that it has submitted ... and Infectious Diseases (NIAID) under BAA-NIAID-DMID-NIHAI2010097 Development Of ...
... colleague Professor Kostya Novoselov won the 2010 Nobel Prize ... modified it to make fluorographene a one-molecule-thick material ... and is basically a two-dimensional version of Teflon, showing ... The results are this week reported in the ...
... often indicate that a device,s clock needs resetting. ... Georgia Tech, the blinking number on a small LCD ... conventional electronic devices with nanoscale generators that harvest mechanical ... nanowires. In this case, the mechanical energy comes ...
Cached Biology Technology:Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Graphene gets a Teflon makeover 2Graphene gets a Teflon makeover 3Nanogenerators grow strong enough to power small conventional electronics 2Nanogenerators grow strong enough to power small conventional electronics 3Nanogenerators grow strong enough to power small conventional electronics 4
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... University of Geneva have discovered a genetic mechanism that defines ... only a secondary role. The research published in Cell ... found in a DNA sequence that was thought, incorrectly, to ... when combined with one another, modulate the activity of the ...
... in line with the principles laid down in the ... which the upcycling and use of waste as raw ... Added to the environmental benefits, the use of ... with enhanced noise absorption properties. So the new barriers ...
... Royal Institute of Technology say they have found further proof ... traced to southern East Asia -- findings that run counter ... the Middle East. Dr Peter Savolainen, KTH researcher in ... that an Asian region south of the Yangtze River was ...
Cached Biology News:Finger (mal)formation reveals surprise function of desert DNA 2Genetic study confirms: First dogs came from East Asia 2
... Our Smart Solutions has now entered ... Screening (HCS) by partnering up with Cellomics, ... from the integration of Beckman Coulter‘s automated ... uncovers deeper biological information at the sub-cellular ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... demands on cell and tissue culture assumes ... Therefore, both cell concentration and percentage of ... precisely. The new Vi-CELLTM Cell Viability Analyzer ... to perform the trypan blue dye exclusion ...
... a post-translational modification that plays an ... immune regulation, inflammation, cell-to-cell adhesion, and ... two lectin based Glycoprotein Isolation Kits, ... Agglutinin (WGA), that allow isolation of ...
Biology Products: